BamSEC and AlphaSense Join Forces
Learn More

City Therapeutics Inc. – Material Contracts

NASDAQ: CTY    
Share price (11/6/26): $18.25    
Market cap (11/6/26): $919 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.9
from S-1/A 20 pages City Therapeutics, Inc. Executive Severance Plan and Summary Plan Description
12/34/56
EX-10.8
from S-1/A 7 pages City Therapeutics, Inc. Compensation Recovery Policy Adopted as of September 19, 2026, Subject to Effectiveness of the Company’s Registration Statement on Form S-1 for Its Initial Public Offering
12/34/56
EX-10.7
from S-1/A 2 pages City Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.6
from S-1/A 3 pages City Therapeutics, Inc. Senior Executive Cash Incentive Bonus Plan
12/34/56
EX-10.3
from S-1/A 10 pages City Therapeutics, Inc. 2026 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 45 pages City Therapeutics, Inc. 2026 Stock Option and Incentive Plan
12/34/56
EX-10.18
from S-1 53 pages Lease Agreement
12/34/56
EX-10.17
from S-1 6 pages City Therapeutics, Inc. May 8th , 2024
12/34/56
EX-10.16
from S-1 6 pages City Therapeutics, Inc. March 21, 2025
12/34/56
EX-10.15
from S-1 6 pages City Therapeutics, Inc. November 9, 2024
12/34/56
EX-10.14
from S-1 6 pages November 10, 2023 John Maraganore via Email
12/34/56
EX-10.13
from S-1 5 pages Consulting Agreement
12/34/56
EX-10.12
from S-1 34 pages All Provisions Are Subject to Addition, Elimination or Revision by Either Party. All Provisions, Communications and Discussions Are Tentative Until Execution of a Written Agreement by Both Parties. Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Exclusive License Agreement Agt. No. A2024-0103
12/34/56
EX-10.11
from S-1 56 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Research Collaboration and License Agreement Between City Therapeutics, Inc. and Bausch + Lomb Ireland Limited July 8, 2024 Research Collaboration and License Agreement
12/34/56
EX-10.10
from S-1 94 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Research Collaboration and License Agreement by and Between Biogen Ma Inc. and City Therapeutics, Inc. Dated May 23, 2025
12/34/56
EX-10.5
from S-1 17 pages City Therapeutics, Inc. Form of Employee Director / Officer Indemnification Agreement
12/34/56
EX-10.4
from S-1 17 pages City Therapeutics, Inc. Form of Non-Employee Director Indemnification Agreement
12/34/56
EX-10.1
from S-1 94 pages City Therapeutics, Inc. 2023 Stock Plan Adopted on July 17, 2023
12/34/56
EX-10.16
from DRS/A 53 pages Lease Agreement
12/34/56
EX-10.1
from DRS/A 94 pages City Therapeutics, Inc. 2023 Stock Plan Adopted on July 17, 2023
12/34/56